The brain possesses a system to get rid of unwanted substances, named Glymphatic System (GS). When this system is faulty, these accumulate, there is local inflammation, and progressive death of the cells. This occurs in neurological diseases including Parkinson's, or Alzheimer's. Inflammation and progressive death of the cells are also present in another neurological disorder, named Multiple Sclerosis (MS). Doctors think that GS dysfunction plays a role in MS too. In this research therefore, the aim is to study whether it drives inflammation, and disease progression in MS patients. The researchers have developed a new way to find signs of alteration of the GS using a scan named Magnetic Resonance Imaging (MRI) and will use it in a pilot study on patients with a condition named Clinically Isolated Syndrome (CIS), which often represents the very beginning of MS. It would therefore be demonstrated that the GS is a new mechanism of disease in CIS, which may associate with the symptoms, or the alterations in the levels of some substances in the blood suggestive of brain cells damage. Should this study be successful, this would provide preliminary evidence to perform a larger research study to assess if GS dysfunction drives the progression of MS.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
To determine that patients with CIS display alterations of the glymphatic system visible in vivo by Structural MRI
Timeframe: Through study completion, an average of 7 days
To determine that patients with CIS display alterations of the glymphatic system visible in vivo by microstructural MRI
Timeframe: Through study completion, an average of 7 days
To determine that patients with CIS display alterations of the glymphatic system visible in vivo by diffusion-weighted MRI
Timeframe: Through study completion, an average of 7 days
To determine that patients with CIS display alterations of the glymphatic system visible in vivo by perfusion-MRI
Timeframe: Through study completion, an average of 7 days
To determine that patients with CIS display alterations of the glymphatic system visible in vivo by ALS-MRI
Timeframe: Through study completion, an average of 7 days